• 목록
• 글쓰기
• 게시판 리스트 옵션
  • 수정
  • 삭제

ADHD Medication During Pregnancy and Breastfeeding

Women suffering from ADHD must make a difficult decision on whether to keep or stop taking ADHD medication during pregnancy and breastfeeding. There are few data on how exposure to ADHD for a long time could affect a pregnant fetus.

A recent study published in Molecular Psychiatry demonstrates that children exposed to ADHD medication during pregnancy do not develop neurological disorders such as impaired hearing or vision, febrile seizures, or IQ impairment. The authors acknowledge the need for higher-quality studies.

Risk/Benefit Analysis

Women who are pregnant and take ADHD medication must weigh the benefits of taking it against the possible risks to the foetus. Physicians don't have the data to make unambiguous recommendations but they can provide information on the risks and benefits to aid pregnant women in making informed decisions.

A study published in Molecular Psychiatry found that women who were taking ADHD medications during their early pregnancy did not face a significantly higher risk of fetal cardiac malformations or major birth defects that are structural. Researchers conducted a large population-based study of case control to assess the frequency of major structural defects in infants who were born to mothers who took stimulants during pregnancy. Clinical geneticists and pediatric cardiologists examined the cases to ensure an accurate case classification and to limit the chance of bias.

However, the researchers' study was not without its flaws. The most important issue was that they were not able to differentiate the effects of the medication from the effects of the disorder that is underlying. This limitation makes it difficult to know whether the small differences observed in the groups that were exposed are due to the use of medication or confounding by comorbidities. Additionally the study did not look at the long-term effects of offspring on their parents.

The study did reveal that infants whose mothers had taken ADHD medication during pregnancy were at a more risk of being admitted to the neonatal intensive care unit (NICU) than infants whose mothers had not taken any medication or cut back on their medications prior to or during pregnancy. This was due to central nervous system disorders, and the higher risk of admission was not found to be influenced by which stimulant medications were taken during pregnancy.

Women who took stimulant adhd medication titration medication during pregnancy were also at an elevated chance of having a caesarean delivery or having a baby with low Apgar score (less than 7). These increases appear to be unrelated to the type of medication used during pregnancy.

Researchers suggest that the small risks associated with the use ADHD medications in early pregnancies can be offset by more beneficial outcomes for both baby and mother of continued treatment for the woman's disorder. Physicians should discuss this with their patients and, if possible, assist them in developing strategies for improving their coping skills that can lessen the negative impact of her condition on her daily life and relationships.

Medication Interactions

Many doctors are confronted with the dilemma of whether to keep treatment or stop during pregnancy as more women are diagnosed with ADHD. These decisions are usually taken without clear and authoritative evidence. Instead, physicians must take into account their own experience, the experience of other doctors and the research on the subject.

The issue of potential risks to infants is particularly tricky. The research on this subject is based on observations rather than controlled studies, and a lot of the results are in conflict. Most studies focus on live births, which may underestimate the severity of teratogenic effects leading to abortions or terminations of pregnancy. The study that is discussed in the journal club addresses these limitations, by examining both data on live and deceased births.

Conclusion Some studies have found an association between adhd medications for adults with anxiety medications and certain birth defects however, other studies haven't shown such a relationship. The majority of studies show that there is a neutral, or slightly negative, effect. Therefore, a careful risk/benefit assessment must be conducted in every instance.

It isn't easy, but not impossible for women with ADHD to stop taking their medication. In an article published in the Archives of Women's Mental Health, psychologist Jennifer Russell notes that stopping ADHD medication during pregnancy can a doctor prescribe adhd medication (https://elearnportal.science/wiki/Pay_Attention_Watch_Out_For_How_Natural_ADHD_Medication_Is_Taking_Over_And_What_To_Do_About_It) increase depression, feelings of isolation and family conflict for those suffering from the disorder. A loss of medication may also affect the ability to safely drive and to perform work-related tasks which are essential aspects of daily life for those with ADHD.

She suggests that women who are unsure whether to continue taking medication or stop due to pregnancy, educate their family members, coworkers, and their friends about the condition, the impact on daily functioning and the benefits of continuing the current treatment. It can also help a woman feel more confident in her decision. Certain medications can pass through the placenta. If a patient decides not to take her ADHD medication while breastfeeding, it is important to be aware that the drug may be transferred to her infant.

Birth Defects Risk

As the use of ADHD drugs to treat symptoms of attention deficit hyperactivity disorder (ADHD) increases there are concerns about the effects that the medications could have on fetuses. Recent research published in the journal Molecular Psychiatry has added to the body of knowledge regarding this issue. With two massive data sets researchers were able to look at more than 4.3 million pregnancies to determine whether stimulant medications increased the risk of birth defects. While the overall risk remains low, the researchers discovered that the first-trimester exposure to ADHD medications was linked to an increased risk of specific heart defects, such as ventriculoseptal defect (VSD).

The authors of the study found no association between early use of medication and other congenital anomalies, such as facial clefting or club foot. The findings are in line with previous studies revealing an increase, but not significant, in the risk of heart malformations in women who started taking ADHD medications before pregnancy. The risk grew during the latter part of pregnancy, as many women begin to discontinue their medication.

Women who were taking adhd inattentive type medication medication in the first trimester were more likely require a caesarean delivery, have a low Apgar after delivery and have a baby that needed breathing assistance when they were born. However, the authors of the study were not able to eliminate bias due to selection by restricting the study to women who did not have other medical issues that could have contributed to the findings.

Researchers hope that their study will inform physicians when they see pregnant women. The researchers advise that while discussing the risks and benefits are crucial, the decision about whether to continue or stop medication should be in light of the severity of each woman's adhd non stimulant medication uk symptoms and her needs.

The authors also warn that while discontinuing the medications is an option, it is not an option that is recommended due to the high prevalence of depression and other mental health issues in women who are pregnant or postpartum. Further, the research suggests that women who choose to stop taking their medications are more likely to have a difficult time adjusting to life without them after the baby's arrival.

Nursing

It can be a stressful experience to become a mom. Women who suffer from ADHD may face a lot of challenges when they must manage their symptoms, attend doctor appointments and prepare for the birth of a child and adjust to a new routine. Therefore, many women elect to continue taking their ADHD medications throughout pregnancy.

The risk for breastfeeding infant is minimal because the majority of stimulant medication passes through breast milk in low amounts. The amount of exposure to medications will differ based on dosage, frequency of administration and the time of day. Additionally, different drugs enter the infant's system through the gastrointestinal tract, or through breast milk. The effect on the health of a newborn isn't completely comprehended.

Because of the lack of research, some physicians might be tempted to stop taking stimulant medication during a woman's pregnancy. It's a difficult choice for the woman who must weigh the benefits of taking her medication as well as the risk to the fetus. In the meantime, until more information is available, doctors should inquire with all pregnant patients about their history of ADHD and whether they are planning or taking to take medication during the perinatal time.

Numerous studies have demonstrated that women can continue to take their ADHD medication in a safe manner while breastfeeding and during pregnancy. In the end, an increasing number of patients are choosing to do so and, in consultation with their physician, they have found that the benefits of continuing their current medication far outweigh any potential risks.

Women with ADHD who are planning to breastfeed should seek advice from an expert psychiatrist prior to becoming pregnant. They should discuss their medication with their physician and discuss the advantages and disadvantages of continued treatment, including non-pharmacological management strategies. Psychoeducation should also be provided to help women with ADHD understand their symptoms and the underlying disorder and learn about treatment options and reinforce existing strategies for managing. This should be a multidisciplinary approach with the GPs, obstetricians and psychiatry. Counselling for pregnancy should include the discussion of a plan for management for both the mother as well as the child, monitoring for signs of deterioration, and when necessary, making adjustments to the medication regimen.